{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:34:07Z","timestamp":1785270847857,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00393-017-0285-5","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T06:00:18Z","timestamp":1491544818000},"page":"322-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Famili\u00e4rer Chilblain-Lupus","Familial chilblain lupus"],"prefix":"10.1007","volume":"76","author":[{"given":"C.","family":"Fiehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"285_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","volume":"1238","author":"YJ Crow","year":"2011","unstructured":"Crow YJ (2011) Type I interferonopathies: A\u00a0novel set of inborn errors of immunity. Ann N Y Acad Sci 1238:91\u201398","journal-title":"Ann N Y Acad Sci"},{"key":"285_CR2","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1084\/jem.20161596","volume":"213","author":"MP Rodero","year":"2016","unstructured":"Rodero MP, Crow YJ (2016) Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a\u00a0conceptual overview. J\u00a0Exp Med 213:2527\u20132538","journal-title":"J Exp Med"},{"key":"285_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00281-015-0500-x","volume":"37","author":"MA Lee-Kirsch","year":"2015","unstructured":"Lee-Kirsch MA, Wolf C, Kretschmer S et al (2015) Type I interferonopathies: An expanding disease spectrum of immunodysregulation. Semin Immunopathol 37:349\u2013357","journal-title":"Semin Immunopathol"},{"issue":"2","key":"285_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","volume":"76","author":"N K\u00f6nig","year":"2016","unstructured":"K\u00f6nig N, Fiehn C, Wolf C et al (2016) Familial chilblain lupus due to a\u00a0gain-of-function mutation in STING. Ann Rheum Dis 76(2):468\u2013472","journal-title":"Ann Rheum Dis"},{"key":"285_CR5","first-page":"463","volume":"31","author":"S Padeh","year":"2013","unstructured":"Padeh S, Gerstein M, Greenberger S, Berkun Y (2013) Chronic chilblains: The clinical presentation and disease course in a\u00a0large paediatric series. Clin Exp Rheumatol 31:463\u2013468","journal-title":"Clin Exp Rheumatol"},{"key":"285_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu Y, Jesus AA, Marrero B et\u00a0al (2014) Activated STING in a\u00a0vascular and pulmonary syndrome. N\u00a0Engl J Med 371:507\u2013518","journal-title":"N Engl J Med"},{"key":"285_CR7","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.chest.2016.02.682","volume":"150","author":"C Picard","year":"2016","unstructured":"Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, Crestani B, Belot A, Thivolet-B\u00e9jui F, Secq V, M\u00e9nard C, Reynaud-Gaubert M, Reix P (2016) Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 Mutation). Chest 150:e65\u2013e71","journal-title":"Chest"},{"key":"285_CR8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.4049\/jimmunol.1500969","volume":"195","author":"EE Gray","year":"2015","unstructured":"Gray EE, Treuting PM, Woodward JJ, Stetson DB (2015) Cutting Edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi-Gouti\u00e8res syndrome. J\u00a0Immunol 195:1939\u20131943","journal-title":"J Immunol"},{"key":"285_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1086\/507848","volume":"79","author":"MA Lee-Kirsch","year":"2006","unstructured":"Lee-Kirsch MA, Gong M, Schulz H, R\u00fcschendorf F, Stein A, Pfeiffer C, Ballarini A, Gahr M, Hubner N, Linn\u00e9 M (2006) Familial chilblain lupus, a\u00a0monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 79:731\u2013737","journal-title":"Am J Hum Genet"},{"key":"285_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/513443","volume":"80","author":"G Rice","year":"2007","unstructured":"Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, Robins P, Harvey S, Hollis T, O\u2019Hara A, Herrick AL, Bowden AP, Perrino FW, Lindahl T, Barnes DE, Crow YJ (2007) Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 80:811\u2013815","journal-title":"Am J Hum Genet"},{"key":"285_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamadermatol.2014.3438","volume":"151","author":"C G\u00fcnther","year":"2015","unstructured":"G\u00fcnther C, Berndt N, Wolf C, Lee-Kirsch MA (2015) Familial chilblain lupus due to a\u00a0novel mutation in the exonuclease III domain of 3\u2019 repair exonuclease 1 (TREX1). JAMA Dermatol 151:426\u2013431","journal-title":"JAMA Dermatol"},{"key":"285_CR12","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2013.04.020","volume":"69","author":"C G\u00fcnther","year":"2013","unstructured":"G\u00fcnther C, Hillebrand M, Brunk J, Lee-Kirsch MA (2013) Systemic involvement in TREX1-associated familial chilblain lupus. J\u00a0Am Acad Dermatol 69:e179\u2013e181","journal-title":"J Am Acad Dermatol"},{"key":"285_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ana.410150109","volume":"15","author":"J Aicardi","year":"1984","unstructured":"Aicardi J, Goutieres F (1984) A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 15:49\u201354","journal-title":"Ann Neurol"},{"key":"285_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/art.27367","volume":"62","author":"G Ramantani","year":"2010","unstructured":"Ramantani G, Kohlhase J, Hertzberg C, Innes AM, Engel K, Hunger S, Borozdin W, Mah JK, Ungerath K, Walkenhorst H, Richardt HH, Buckard J, Bevot A, Siegel C, von St\u00fclpnagel C, Ikonomidou C, Thomas K, Proud V, Niemann F, Wieczorek D, H\u00e4usler M, Niggemann P, Baltaci V, Conrad K, Lebon P, Lee-Kirsch MA (2010) Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Gouti\u00e8res syndrome. Arthritis Rheum 62:1469\u20131477","journal-title":"Arthritis Rheum"},{"key":"285_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/rheumatology\/kes181","volume":"52","author":"J Abe","year":"2013","unstructured":"Abe J, Izawa K, Nishikomori R, Awaya T, Kawai T, Yasumi T, Hiragi N, Hiragi T, Ohshima Y, Heike T (2013) Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a\u00a0family with Aicardi-Goutieres syndrome\/familial chilblain lupus. Rheumatology (Oxford) 52:406\u2013408","journal-title":"Rheumatology (Oxford)"},{"issue":"A","key":"285_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ajmg.a.33778","volume":"155","author":"JC Ravenscroft","year":"2011","unstructured":"Ravenscroft JC, Suri M, Rice GI, Szynkiewicz M, Crow YJ (2011) Autosomal dominant inheritance of a\u00a0heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med Genet\u00a0A 155(A):235\u2013237","journal-title":"Am J Med Genet A"},{"key":"285_CR17","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1073\/pnas.1423804112","volume":"112","author":"JL Grieves","year":"2015","unstructured":"Grieves JL, Fye JM, Harvey S, Grayson JM, Hollis T, Perrino FW (2015) Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease. Proc Natl Acad Sci USA 112:5117\u20135122","journal-title":"Proc Natl Acad Sci USA"},{"key":"285_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10875-015-0147-3","volume":"35","author":"GI Rice","year":"2015","unstructured":"Rice GI, Rodero MP, Crow YJ (2015) Human disease phenotypes associated with mutations in TREX1. J\u00a0Clin Immunol 35:235\u2013243","journal-title":"J Clin Immunol"},{"key":"285_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cell.2008.06.032","volume":"134","author":"DB Stetson","year":"2008","unstructured":"Stetson DB, Ko JS, Heidmann T, Medzhitov R (2008) Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587\u2013598","journal-title":"Cell"},{"key":"285_CR20","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1136\/annrheumdis-2013-204845","volume":"74","author":"S Kretschmer","year":"2015","unstructured":"Kretschmer S, Wolf C, K\u00f6nig N, Staroske W, Guck J, H\u00e4usler M, Luksch H, Nguyen ALA, Kim B, Alexopoulou D, Dahl A, Rapp A, Cardoso MC, Shevchenko A, Lee-Kirsch ME (2015) 1SAMHD1 prevents autoimmunity by maintaining genome stability. Ann Rheum Dis 74:e17","journal-title":"Ann Rheum Dis"},{"key":"285_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamadermatol.2015.0251","volume":"151","author":"J Munoz","year":"2015","unstructured":"Munoz J, Rodi\u00e8re M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, Rozenberg F, Crow YJ, Bessis D (2015) Stimulator of interferon genes-associated vasculopathy with onset in infancy: A mimic of childhood Granulomatosis with Polyangiitis. JAMA Dermatol 151:872\u2013877","journal-title":"JAMA Dermatol"},{"key":"285_CR22","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1172\/JCI79100","volume":"124","author":"N Jeremiah","year":"2014","unstructured":"Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, Goudin N, Fr\u00e9mond ML, Nitschke P, Molina TJ, Blanche S, Picard C, Rice GI, Crow YJ, Manel N, Fischer A, Bader-Meunier B, Rieux-Laucat F (2014) Inherited STING-activating mutation underlies a\u00a0familial inflammatory syndrome with lupus-like manifestations. J\u00a0Clin Invest 124:5516\u20135520","journal-title":"J Clin Invest"},{"key":"285_CR23","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler EC, Batliwalla FM, Karypis G et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2610\u20132615","journal-title":"Proc Natl Acad Sci USA"},{"key":"285_CR24","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.38628","volume":"66","author":"L Chiche","year":"2014","unstructured":"Chiche L, Jourde-Chiche N, Whalen E et al (2014) Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheum 66:1583\u20131595","journal-title":"Arthritis Rheum"},{"key":"285_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W (2016) CD1067 study investigators. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: A\u00a0randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75:1909\u20131916","journal-title":"Ann Rheum Dis"},{"key":"285_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00393-015-0027-5","volume":"75","author":"C G\u00fcnther","year":"2016","unstructured":"G\u00fcnther C, Schmidt F, K\u00f6nig N, Lee-Kirsch MA (2016) Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons. Z\u00a0Rheumatol 75:134\u2013140","journal-title":"Z Rheumatol"},{"key":"285_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/ng2091","volume":"39","author":"MA Lee-Kirsch","year":"2007","unstructured":"Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U, Bailey SL, Witte T, Vyse TJ, Kere J, Pfeiffer C, Harvey S, Wong A, Koskenmies S, Hummel O, Rohde K, Schmidt RE, Dominiczak AF, Gahr M, Hollis T, Perrino FW, Lieberman J, H\u00fcbner N (2007) Mutations in the gene encoding the 3\u2019-5\u2019 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39:1065\u20131067","journal-title":"Nat Genet"},{"key":"285_CR28","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","volume":"194","author":"J An","year":"2015","unstructured":"An J, Woodward JJ, Sasaki T, Minie M, Elkon KB (2015) Cutting edge: Antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction. J\u00a0Immunol 194:4089\u20134093","journal-title":"J Immunol"},{"key":"285_CR29","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1136\/annrheumdis-2016-210565","volume":"75","author":"V T\u00fcngler","year":"2016","unstructured":"T\u00fcngler V, K\u00f6nig N, G\u00fcnther C, Engel K, Fiehn C, Smitka M, von der Berner HMR, Lee-Kirsch MA (2016) Response to: \u2019JAK inhibition in STING-associated interferonopathy\u2019 by Crow et al. Ann Rheum Dis 75:e76","journal-title":"Ann Rheum Dis"},{"key":"285_CR30","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","volume":"138","author":"M-L Fr\u00e9mond","year":"2016","unstructured":"Fr\u00e9mond M\u2011L, Rodero MP, Jeremiah N et al (2016) Efficacy of the Janus kinase \u00bd inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3\u00a0children. J\u00a0Allergy Clin Immunol 138:1752\u20131755","journal-title":"J Allergy Clin Immunol"},{"key":"285_CR31","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1136\/annrheumdis-2016-210504","volume":"75","author":"MP Rodero","year":"2016","unstructured":"Rodero MP, Fr\u00e9mond ML, Rice GI, Neven B, Crow YJ (2016) JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis 75:e75","journal-title":"Ann Rheum Dis"},{"key":"285_CR32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","volume":"136","author":"J Wenzel","year":"2016","unstructured":"Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D (2016) AK1\/2 inhibitor Ruxolitinib controls a\u00a0case of chilblain lupus Erythematosus. J\u00a0Investig Dermatology 136:1281\u20131283","journal-title":"J Investig Dermatology"},{"key":"285_CR33","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N\u00a0Engl J Med 371:2537\u20132538","journal-title":"N Engl J Med"},{"key":"285_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y et\u00a0al (2015) Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib. EBioMedicine 2:351\u2013355","journal-title":"EBioMedicine"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0285-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0285-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0285-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T11:38:01Z","timestamp":1493811481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0285-5"}},"subtitle":["Typ-I-Interferonopathie mit Modellcharakter","Type 1 interferonopathy with model character"],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0285-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}